The Leicester oncology service covers the full range of adult cancers, offering chemotherapy and radiotherapy (external beam, brachytherapy and unsealed) to over one million local residents and an extended catchment of up to five million.
We are one of 16 centres nationally that offer stereotactic radiotherapy to lung cancers and oligometastatic disease.
In conjunction with the haematology department, we offer three wards accommodating 57 patients, an assessment unit and a day-case facility, which is covered by a daily consultant. We also offer an outreach acute oncology service to the rest of the hospital with same day consultant review.
Our radiotherapy unit in oncology has LINACS to provide intensity modulated radiotherapy and stereotactic radiotherapy. The chemotherapy unit has a sterile lab and suite for both inpatients and ambulatory patients.
There are no current waiting lists for our treatment and closely integrated working patterns exist between surgical, medical and clinical oncologists and palliative care teams.
Our oncology team comprises 16 consultant posts (seven medical oncology and nine clinical oncology, four of which are academic), nine specialty trainee doctors and six FY and CT doctors.
Our developing relationship with Northamptonshire has established the South East Midlands Oncology Centre, with potential for increased trials recruitment, efficiencies of delivery and service improvement.
The unit offers a wide range of educational opportunities, including regular educational meetings for all grades, weekly seminars for FY/CT doctors, exam oriented ST radiotherapy training, CMT and undergraduate training. Each year, about 250 medical students receive teaching in a variety of settings.
We hold a good track record in the supervision of academic clinical fellows and lecturers, with excellent exam pass rates. Trainees are encouraged to undertake audits and attend an annual chemotherapy course.
We’ve established strong links with the University of Leicester and are globally renowned for research. As well as offering a CRUK cancer centre and experimental cancer medicine centre, we house the Hope Clinical Trials Facility, which supports all phases of studies, and also provide the only phase one centre in the Midlands.
Our clinical research primarily focuses on early phase trials of novel agents and a portfolio of phase three trials. We’ve secured extensive funding from Cancer Research UK, Leukaemia and Lymphoma Research Fund, MRC and Hope Foundation, and have recently won the CRUK accelerator award.